Drug Profile
V 935
Alternative Names: V934; V934/V935; V935Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Geron Corporation; Merck & Co
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IM, Injection)
- 04 Dec 2008 Phase-I clinical trials in Solid tumours in USA (IM)
- 13 Dec 2007 Merck files an IND with the FDA in the US for the cancer vaccine